← Feed

u/Confident-Web-7118

3 theses · first seen Oct 20, 2026
WindowThesesResolvedWinsWin rateAvg returnMedian return
1d22150%+0.5%+0.5%
3d33267%+0.2%+2.7%
1w33267%+11.5%+13.4%
1m33267%+17.8%+17.8%
3m333100%+89.6%+93.4%
6m333100%+200.9%+224.3%
1y000———

Past performance does not predict future results. Informational only, not investment advice.

Thesis history

$SLSr/pennystocksDDbullish
u/Confident-Web-7118 · 227d ago2 prior · 100% at 3mo
“Owns 809K shares and is continuously accumulating every week”

$SLS (Deepest Due Diligence for SLS-009, Machine Learning Models and Results, and Buyout Deep DD) (From a Deep Value Investor)

Author's 16-model ML ensemble predicts SLS-009 (Tambiciclib) will achieve 64.4% ORR and 61.1% CR/CRi in the IMPACT-AML Phase 2B trial, far exceeding the FDA's 17% CR/CRi bar for accelerated approval in AML. Combined with GPS's >99% REGAL Phase 3 success probability, SLS owns the complete AML treatment journey (induction + maintenance), creating substantial acquisition value.

At post $5.04Now $10.16+101.5% since postedas of Oct 29, 4:01 PM ET
1d-1.8%
3d-5.6%
1w-0.8%
1m-2.2%
3m+53.4%
6m+129.2%
1y—
original post →
$SLSr/pennystocksDDbullish
u/Confident-Web-7118 · 254d ago2 prior · 100% at 3mo
Long 805,000 shares of SLS

$SLS Part 2 and FINAL (Deepest Due Diligence for REGAL Trial) (From a Deep Value Investor) (Predicting BAT mOS from Predictive Model)

Author's statistical model predicts BAT median OS of 11.4 months with 99% accuracy, implying the REGAL trial will crush the 0.636 hazard ratio threshold with expected topline Cox HR of 0.35-0.50 and 99.9% posterior success probability. GPS vaccine is positioned to become the standard of care in AML CR2 if BAT mOS stays below 16-20 months. Author owns 805K shares and views SLS as a rare asymmetric opportunity with insane margin of safety.

At post $4.04Now $10.16+151.4% since postedas of Oct 29, 4:01 PM ET
1d+2.7%
3d+2.7%
1w+21.8%
1m+17.8%
3m+122.0%
6m+224.3%
1y—
original post →
$SLSr/pennystocksDDbullish
u/Confident-Web-7118 · 257d ago2 prior · 100% at 3mo
“805K shares, continuously accumulating every week”

$SLS (Deepest Due Diligence for REGAL Trial) (From a Deep Value Investor)

SELLAS Life Sciences' GPS vaccine in the REGAL Phase 3 trial for AML patients in second remission shows a deceleration in event rates (only 12 deaths in 12 months from 66 at-risk patients) that indicates a cure-fraction model. The author's model predicts a 42-48% cure fraction and hazard ratio of 0.35-0.50 (well below the 0.636 trial threshold), positioning GPS as a monopoly standard-of-care treatment for 5-8 years.

At post $3.66Now $10.16+177.5% since postedas of Oct 29, 4:01 PM ET
1d—
3d+3.6%
1w+13.4%
1m+37.7%
3m+93.4%
6m+249.2%
1y—
original post →

End of results.